Merck plans to acquire biotechnology company Cidara Therapeutics for $9.2 billion.

On November 14, Merck & Co. announced a final agreement with the biotechnology company Cidara Therapeutics. According to the agreement, Merck will acquire Cidara through a subsidiary for $221.50 per share in cash, with a total transaction value of approximately $9.2 billion.